Covid-19, Cuban drug Nimotuzumab granted Health Registration in Indonesia

By Cristiano Antonino On Aug 27, 2022

The monoclonal antibody Nimotuzumab has demonstrated, during several years of clinical trials, its efficacy in the treatment of patients with cancer, and more recently in the use for the therapy of severe forms of COVID-19

The monoclonal antibody CIMAher -known as Nimotuzumab, created by the Centre for Molecular Immunology (CIM)- was recently granted Health Registration in Indonesia

CIM, spreading the news through its Twitter account, detailed that the drug was registered in the Asian country through the joint venture InnoCIMAb, formed by Cuba and Singapore.

He then pointed out that the establishment of this important event means an increase in sales of this product in this country and another recognition of the quality of our science.

The monoclonal antibody Nimotuzumab has demonstrated during several years of clinical trials its efficacy in the care of patients with cancer and more recently in the use for the therapy of severe forms of COVID-19

In 2002, it was granted medical registration for the treatment of advanced head and neck cancer and is currently used as a therapy for nasopharyngeal, oesophageal, pancreatic and lung cancer with non-small cell cancers.

It is registered in several countries and has special marketing permission in 15 territories in Europe and other countries, including Singapore.

Cuba, Covid Soberana 02 And Abdala Vaccines Also Effective Against Omicron In 90% Of Cases

Omicron Variant: What Is It And What Are The Symptoms Of The Infection?

What Heart And Stroke Patients Need To Know About COVID-19 In 2022